Phase II Study of Irinotecan plus Leucovorin and Bolus 5-Fluorouracil as First- or Second-Line Chemotherapy in Patients with Advanced Gastric or Esophageal-Gastric Junction Adenocarcinoma

References

• Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1–9.
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Kuitunen T, Nyandoto P et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587–591.
   Google Scholar
• Murad A, Santiago F, Petroianu A et al. Modified thera-py with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41.
   Google Scholar
• Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163–168.
   Google Scholar
• Kelsen D, Atiq 0, Saltz L et al. FAMTX versus etopo-side, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541–548.
   PubMed Web of Science ®Google Scholar
• Wils J, Klein H, Wagener D et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin—a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827–831.
   Google Scholar
• Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrex-ate, fluorouracil and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
   Google Scholar
• Webb A, Cunningham D, Scarffe J et al. Randomised trial comparing epirubicin, cisplatin and fluorouracil versus flu-orouracil, doxorubicn and methotrexate in advanced oesopha-gogastric cancer. J Clin Oncol 1997; 15: 261–267.
   Google Scholar
• Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protract-ed venous-infusion fluorouracil (PVI 5FU) with epirubicin, cis-platin and PVI 5FU in advanced oesophagogastric cancer. J Clin Oncol 2002; 20: 1996–2004.
   Google Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000; 343: 905–914.
   Google Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multi-centre randomised trial. Lancet 2000; 355: 1041-1047.
   Google Scholar
• Kohne CH, Catane R, Klein B et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: A phase II multicentric trial. Br J Cancer 2003; 89: 997–1001.
   Google Scholar
• Lin-Shin L, Hecht J. A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction. Proc Am Soc Clin Oncol 2000; 19: 289a.
   Google Scholar
• Hecht J, Parson M, Lee R. A phase II trial of irinote-can (CPT-11) in patients with adenocarcinoma of the esopha-gus and gastric cardia. Proc Am Soc Clin Oncol 1999; 18: 287a.
   Google Scholar
• Futatsuki K, Wakui A, Nakao I et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric can-cer: CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994; 21: 1033–1038.
   Google Scholar
• Ohtsu A, Shimada Y, Shirao K et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cis-platin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JC0G9205). J Clin Oncol 2003; 21: 54–59.
   Google Scholar
• Kim NK, Park YS, Heo DS et al. A phase III random-ized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813–3818.
   Google Scholar
• Coombes RC, Chilvers CE, Amadori D et al. Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer: An International Collaborative Cancer Group (ICCG) study. Ann Oncol 1994; 5: 33–36.
   Google Scholar
• Johnson PW, Thompson PI, Seymour MT et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 1991; 64: 603–605.
   Google Scholar
• Louvet C, de Gramont A, Demuynck B et al. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann Oncol 1991; 2: 229–230.
   Google Scholar
• Rubin J, Gallagher JG, Schroeder G et al. Phase II tri-als of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996; 78: 1888–1891.
   Google Scholar
• Machover D, Goldschmidt E, Chollet P et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-flu-orouracil and high-dose folinic acid. J Clin Oncol 1986; 4: 685–696.
   Google Scholar
• Blanke CD, Haller DG, Benson AB et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 2001; 12: 1575–1580.
   Google Scholar
• Assersohn L, Brown G, Cunningham D et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64–69.
   Google Scholar
• Findlay MPN, Ackland S, Gebski V et al. Phase II study of irinotecan, leucovorin and 5FU (ILF) in advanced gastric cancer. Proc Am Soc Clin Oncol 2001; 20: 165a.
   Google Scholar
• Wagner AD, Grothe W, Haerting J et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
   Google Scholar
• Bouche O, Raoul JL, Bonnetain F et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group study-FFCD 9803. J Clin Oncol 2004; 22: 4319-4328.
   Google Scholar
• Moehler M, Eimermacher A, Siebler J et al. Randomized phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucov-orin, and etoposide (ELF) in untreated metastatic gastric can-cer. Br J Cancer 2005; 92: 2122–2128.
   Google Scholar
• Dank M, Zaluski J, Valvere V et al. Randomized phase III trial of irinotecan (CPT 11) + 5- FU/folinic acid (FA) vs CDDP + 5-FU in first line advanced gastric cancer patients. J Clin Oncol 2005; 23: 308s (suppl 16, abstr 4003).
   Google Scholar
• Kalofonos HP, Skarlos D, Bafaloukos D et al. A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluo-rouracil in patients with advanced colorectal carcinoma. Cancer Invest. 2003; 21: 855–862.
   Google Scholar
• Kalofonos HP, Aravantinos G, Kosmidis P et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluo-rouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 2005; 16: 869–877.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205–216.
   PubMed Web of Science ®Google Scholar
• Roth AD. Multimodality management of metastatic gas-tric and esophageal cancer. ASCO Educational Book 2004: 199–204.
   Google Scholar
• Pozzo C, Barone C, Szanto J et al. Irinotecan in combi-nation with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004; 15: 1773–1781.
   Google Scholar
• Fazio N, Zampino G, Nole F et al. Irinotecan combined with infusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemotherapy. Proc Am Soc Clin Oncol 2004; 22: 4146.
   Google Scholar
• Kim ST, Kang WK, Kang JH et al. Salvage chemother-apy with irinotecan, 5-fluorouracil and leucovorin for taxane-and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 2005; 92: 1850–1854.
   Google Scholar